BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics.

BostonGene was founded in 2015 by Andrew Feinberg. The company is headquartered in Waltham, MA.


BostonGene’s innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system, and the effectiveness of all available approved and investigational treatments.


The BostonGene Tumor Portrait™ Tests, a sophisticated analysis of the tumor and tumor microenvironment (TME), reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response to diverse therapies, and recommended therapies.


BostonGene’s integrated model of tumor genetics, transcriptomics, microenvironment, and tumor composition provides a 360° overview of a patient tumor to give physicians invaluable insights into potential treatment options.


BostonGene is backed by NEC Corporation, Impact Investment Capital, Japan Industrial Partners, and others. The company raised $150M in Series B round on Apr 06, 2022. This brings BostonGene's total funding to $200M to date. The latest round mints BostonGene a unicorn with a valuation of over $1B post-money.



  • Year founded: 2015
  • Funding Info: $200M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: Valued at over $1B as of Apr 06, 2022
  • City/Town: Waltham
  • State: Massachusetts
  • Country: United States
Related businesses